Novavax, COVID-19
Make Room, mRNA: What to Know About the Novavax COVID Vaccine
In addition to Pfizer and Moderna's new formulas, Novavax's protein-based shot is an option for COVID vaccination this season.
Canada not ordering Novavax protein-based COVID vaccine this year due to low demand
TORONTO — The Public Health Agency of Canada says it is not providing Novavax’s COVID-19 vaccine this respiratory virus season, citing lack of demand. It says the manufacturer requires a minimum order of its updated protein-based vaccine, called Nuvaxovid, which far exceeds the uptake by Canadians last year.
Canadian government not ordering Novavax's protein-based COVID-19 vaccine this year
The Public Health Agency of Canada says it is not providing Novavax’s COVID-19 vaccine this respiratory virus season, citing low demand.
Is the Novavax COVID-19 Vaccine Better?
While the new mRNA vaccines from Moderna and Pfizer-BioNTech have dominated the COVID-19 vaccine story, there is another type of shot that uses a more traditional vaccine-making technology, used by Novavax.
On the hunt for Novavax: Why people are seeking out the 'traditional' COVID vaccine
Some people are making it their mission to get Novavax, rather than Pfizer or Moderna, for their COVID booster.
Canada won’t be ordering Novavax’s updated COVID-19 vaccine, cites low demand
The Public Health Agency of Canada says a very small portion of the doses ordered in 2023 were used and that its decision reflects efforts to limit vaccine wastage.
Health Canada approves Novavax's updated COVID-19 vaccine for fall
Health Canada said Thursday it has authorized Novavax's updated COVID-19 vaccine for those aged 12 years and up.
Bay Area health officials encourage residents to get updates COVID vaccines
Read more: <a href=" Shohei Ohtani becomes the first major league player to exceed 50 homers and 50 steals in a season What to Do With Old Cell Phones (Because You Can’t Throw Them Away) House members bypass Mike Johnson a second time to force Social Security vote What’s on TV tonight: James Herriot returns in All Creatures Great and Small Researchers Study Life After Death — And It Gets Weirder 12 States Trying To Ban Gas Powered Cars (Even Though Voters Want Them) I’ve been retired in Mexico for 6 years—it's a luxury that ‘presents a new,
Health Canada approves updated Novavax COVID-19 vaccine
Health Canada has authorized Novavax's updated COVID-19 vaccine that protects against currently circulating variants of the virus.
CNET on MSN2d
Move Over, mRNA: What to Know About the Novavax COVID Vaccine
Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.
MarketWatch1d
Novavax Inc. stock underperforms Monday when compared to competitors
Shares of Novavax Inc. NVAX shed 5.04% to $12.63 Monday, on what proved to be an all-around great trading session for the ...
bovnews1d
What’s Fueling Novavax Inc (NVAX) Stock’s 48.65% Gain Above Its 200-Day SMA?
On Friday, Novavax Inc (NVAX) stock saw a modest uptick, ending the day at $13.3 which represents a slight increase of $1.15 or 9.47% from the prior close of $12.15. The stock opened at $12.32 and ...
Yahoo Finance1d
Novavax, Inc. (NVAX)
Novavax stock remains volatile. After hitting a two-year high in June on enthusiasm for its updated Covid vaccine, shares have pulled back. Recently, Zacks.com users have been paying close ...
The turnaround man
Novavax occupies five sites in Montgomery County totaling about 370,000 square feet. Its footprint includes its headquarters ...
Zacks.com on MSN6d
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...
Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...
Former Harmony CEO John Jacobs reshaping D.C. biotech with multibillion-dollar Sanofi deal
John Jacobs left Plymouth Meeting's Harmony Biosciences in 2023 after overseeing its IPO. Now, he's got another biotech firm ...